IR-Crizotinib
IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC50=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research.
For research use only. We do not sell to patients.
- CAS No.: 2387927-74-2
- Formula: C53H57Cl2FIN7O
- Molecular Weight:1024.87
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
IC50: NF-κB-inducing kinase (3.381 μM)[1].
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| GBM | EC50 |
15 nM
Compound: 1
|
Synergistic antiproliferative activity against patient-derived GBM cells assessed as cell viability after 48 hrs in presence of temozolomide by 5-Ethynyl-2'-deoxyuridine incorporation assay
Synergistic antiproliferative activity against patient-derived GBM cells assessed as cell viability after 48 hrs in presence of temozolomide by 5-Ethynyl-2'-deoxyuridine incorporation assay
|
[PMID: 31378572] |
| GBM | EC50 |
50 nM
Compound: 1
|
Antiproliferative activity against patient-derived GBM cells assessed as cell viability after 48 hrs by 5-Ethynyl-2'-deoxyuridine incorporation assay
Antiproliferative activity against patient-derived GBM cells assessed as cell viability after 48 hrs by 5-Ethynyl-2'-deoxyuridine incorporation assay
|
[PMID: 31378572] |
| GBM | EC50 |
93.1 nM
Compound: 1
|
Cytotoxicity against patient-derived GBM cells assessed as LDH release after 96 hrs by spectrophotometric method
Cytotoxicity against patient-derived GBM cells assessed as LDH release after 96 hrs by spectrophotometric method
|
[PMID: 31378572] |
| GBM | IC50 |
1 nM
Compound: 1
|
Synergistic antiproliferative activity against patient-derived GBM cells assessed as reduction in cell viability after 48 hrs in presence of temozolomide by 5-Ethynyl-2'-deoxyuridine incorporation assay
Synergistic antiproliferative activity against patient-derived GBM cells assessed as reduction in cell viability after 48 hrs in presence of temozolomide by 5-Ethynyl-2'-deoxyuridine incorporation assay
|
[PMID: 31378572] |
| GBM | IC50 |
4.7 nM
Compound: 1
|
Antiproliferative activity against patient-derived GBM cells assessed as reduction in cell viability after 48 hrs by 5-Ethynyl-2'-deoxyuridine incorporation assay
Antiproliferative activity against patient-derived GBM cells assessed as reduction in cell viability after 48 hrs by 5-Ethynyl-2'-deoxyuridine incorporation assay
|
[PMID: 31378572] |
Chemical Information
-
CAS No. 2387927-74-2
-
Molecular Weight 1024.87
-
Formula C53H57Cl2FIN7O
-
SMILES
NC(C(O[C@@H](C1=C(Cl)C=CC(F)=C1Cl)C)=C2)=NC=C2C3=CN(N=C3)C4CCN(C5=C(/C=C/C6=[N+](C)C(C=CC=C7)=C7C6(C)C)CCC/C5=C\C=C8C(C)(C)C(C=CC=C9)=C9N/8C)CC4.[I-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz